Insulin Like Growth F-1 Test in Karachi at Dr. Essa Lab

Insulin Like Growth F-1 at Dr. Essa Lab

The Insulin Like Growth F-1 (IGF-1) test, also historically referred to as somatomedin C, is a highly specialized clinical laboratory investigation utilized to assess growth-related disorders and pituitary gland function. Synthesized primarily by the liver in response to growth hormone (GH) stimulation, IGF-1 serves as the primary mediator of the physiological actions of growth hormone throughout the human body. Unlike growth hormone, which is secreted in a highly pulsatile and unpredictable manner throughout the day, serum concentrations of Insulin Like Growth F-1 remain remarkably stable. This physiological stability makes the IGF-1 assay an invaluable diagnostic tool and a far more reliable indicator of integrated daily growth hormone secretion than a single random growth hormone measurement. At Dr. Essa Lab in Karachi, Pakistan, this test is performed using advanced automated chemiluminescent immunoassay (CLIA) technology, ensuring the highest levels of clinical sensitivity and specificity for patients requiring endocrine evaluation.

The clinical importance of the Insulin Like Growth F-1 test extends across various age groups, from pediatric patients presenting with developmental delays to adults exhibiting signs of hormonal imbalance. In children, IGF-1 is essential for normal skeletal growth and tissue development. Insufficient levels during childhood can lead to severe growth retardation, short stature, and delayed physical development. Conversely, in adults, abnormal elevations of this hormone are typically associated with acromegaly, a chronic and progressive disorder characterized by the overgrowth of bone and soft tissues, most commonly caused by a benign pituitary adenoma. By measuring the precise concentration of IGF-1 in the blood, endocrinologists and general physicians can accurately diagnose these complex conditions, monitor the efficacy of therapeutic interventions, and adjust treatment protocols with high clinical precision.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the clinical accuracy and reliability of the Insulin Like Growth F-1 test results. While a random blood sample can be collected for IGF-1 analysis because its levels do not fluctuate rapidly, clinical guidelines often recommend specific preparation steps to minimize potential confounding factors. Patients are generally advised to fast for 8 to 12 hours prior to the blood draw, particularly if other concurrent endocrine or metabolic tests, such as fasting growth hormone, glucose, or a lipid profile, are scheduled. Adequate hydration is strongly encouraged, as drinking plenty of water makes the veins more accessible and facilitates a smoother venipuncture process. It is critical for patients to inform their healthcare provider and the laboratory staff at Dr. Essa Lab about all current medications, over-the-counter drugs, vitamins, and dietary supplements being taken. In particular, high doses of biotin (Vitamin B7) can interfere with the immunoassay technology used to measure hormone levels, potentially leading to falsely elevated or decreased results. Therefore, patients may be advised to discontinue biotin supplements for at least 48 hours before the test under the guidance of their prescribing physician. Additionally, strenuous physical exercise should be avoided immediately before the blood collection, as intense physical activity can temporarily alter hormone levels in the bloodstream.

During the Procedure

The collection of a blood sample for the Insulin Like Growth F-1 test at Dr. Essa Lab is a routine, safe, and highly standardized venipuncture procedure performed by experienced phlebotomists. Upon arrival at the diagnostic center, the patient is comfortably seated in a specialized blood collection chair. The phlebotomist begins by verifying the patient’s identity and confirming compliance with any pre-test preparation instructions. The skin over the selected vein, typically located in the antecubital fossa of the arm, is thoroughly cleansed with an antiseptic solution to prevent any microbial contamination. A sterile tourniquet is then applied a few inches above the puncture site to increase venous pressure and make the vein more visible and palpable. Using a sterile, single-use needle, the phlebotomist carefully accesses the vein, and blood is drawn into a serum separator tube (SST) or a standard red-top tube. Patients may feel a brief, mild pinch or stinging sensation as the needle enters the skin, but the discomfort is minimal and transient. Once the required volume of blood is collected, the tourniquet is released, the needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze pad to promote hemostasis. A small adhesive bandage is then applied to protect the site. The entire procedure takes less than five minutes, and patients are generally free to resume their normal daily activities immediately afterward. The collected blood sample is then centrifuged to separate the serum, which is subsequently analyzed using state-of-the-art laboratory equipment.

When is an Insulin Like Growth F-1 Performed?

Evaluating Growth Hormone Deficiency in Children

Pediatricians and pediatric endocrinologists frequently request the Insulin Like Growth F-1 test when evaluating children who exhibit signs of abnormal growth patterns or developmental delays. The primary clinical symptom prompting this investigation is a significantly reduced growth velocity, where a child’s height falls well below the third percentile on standardized growth charts or deviates progressively from their established growth curve. Other physical signs may include a youthful facial appearance, delayed dental eruption, poor muscle development, and delayed bone age as confirmed by radiographic imaging. Because growth hormone is released in pulsatile bursts, a single random GH measurement is clinically unhelpful for diagnosing deficiency. Measuring the stable concentration of IGF-1 provides a reliable reflection of the child’s overall growth hormone activity, helping physicians differentiate between familial short stature, constitutional delay of growth, and true growth hormone deficiency, thereby guiding decisions regarding growth hormone replacement therapy.

Diagnosing Acromegaly and Gigantism in Adults and Adolescents

The Insulin Like Growth F-1 test is the gold standard screening tool for diagnosing acromegaly in adults and gigantism in children and adolescents. These rare but serious conditions are characterized by the excessive and uncontrolled production of growth hormone, almost always due to a benign tumor of the pituitary gland known as a pituitary adenoma. In children, before the growth plates of the long bones have fused, excess growth hormone leads to gigantism, resulting in excessive height and rapid skeletal growth. In adults, because the growth plates are already fused, the excess hormone causes acromegaly, which manifests as the gradual enlargement of the hands, feet, jaw, and facial bones, alongside symptoms like joint pain, carpal tunnel syndrome, sleep apnea, and cardiomegaly. Because IGF-1 levels remain elevated and stable throughout the day in patients with these conditions, this test is highly sensitive for detecting pathologic growth hormone excess, allowing for early diagnosis and timely surgical or medical intervention.

Monitoring Growth Hormone Replacement Therapy

For patients diagnosed with growth hormone deficiency who are undergoing recombinant human growth hormone (rhGH) replacement therapy, the Insulin Like Growth F-1 test is an indispensable monitoring tool. Regular measurement of serum IGF-1 concentrations allows endocrinologists to assess the therapeutic efficacy of the treatment and ensure that the dosage is optimized for the individual patient. The primary clinical objective is to maintain the patient’s IGF-1 levels within the age- and sex-adjusted normal reference range. If the IGF-1 levels remain too low, it indicates that the current dosage may be insufficient to achieve the desired therapeutic outcomes, such as improved bone density, muscle mass, and growth velocity. Conversely, excessively high IGF-1 levels indicate over-replacement, which can predispose the patient to adverse side effects similar to those seen in acromegaly, including fluid retention, joint pain, and metabolic disturbances. Regular monitoring at Dr. Essa Lab ensures safe and effective long-term management.

Investigating Pituitary Tumors and Hypopituitarism

The pituitary gland is the master endocrine gland, responsible for regulating multiple hormonal pathways, including the growth hormone-IGF-1 axis. When a patient is suspected of having a pituitary tumor, whether functioning or non-functioning, or is presenting with signs of hypopituitarism (generalized underactivity of the pituitary gland), the Insulin Like Growth F-1 test is performed as part of a comprehensive endocrine panel. Pituitary tumors can physically compress normal pituitary tissue, leading to a progressive loss of hormonal function, with growth hormone secretion often being the first pathway to be compromised. Symptoms of hypopituitarism in adults can be subtle and non-specific, including chronic fatigue, muscle weakness, unexplained weight changes, and decreased libido. By evaluating IGF-1 levels alongside other pituitary hormones such as TSH, ACTH, LH, and FSH, clinicians can comprehensively assess pituitary reserve and formulate targeted treatment strategies, which may include surgery, radiation, or hormone replacement.

Assessing Nutritional Status and Chronic Malnutrition

Beyond its primary role in endocrine diagnostics, the Insulin Like Growth F-1 test serves as a highly sensitive biomarker for evaluating nutritional status and monitoring chronic malnutrition or malabsorption syndromes. Because the synthesis of IGF-1 in the liver is highly dependent on adequate caloric and protein intake, serum concentrations of this hormone drop rapidly during periods of nutritional deprivation, even before significant changes are observed in other traditional markers like serum albumin or prealbumin. Physicians may utilize the IGF-1 test to assess patients suffering from severe eating disorders such as anorexia nervosa, patients undergoing major gastrointestinal surgeries, or individuals with chronic malabsorptive conditions like Celiac disease, Crohn’s disease, or short bowel syndrome. In these clinical scenarios, serial measurements of IGF-1 help healthcare providers monitor the effectiveness of nutritional rehabilitation programs and enteral or parenteral nutrition therapies.

What Does an Insulin Like Growth F-1 Detect?

The Insulin Like Growth F-1 test is capable of detecting a wide spectrum of physiological and pathological states related to the growth hormone axis, hepatic function, and nutritional balance. Specifically, the clinical analysis of serum IGF-1 levels can detect and assist in the diagnosis of: 1. Growth hormone deficiency in pediatric patients presenting with short stature. 2. Acromegaly in adults presenting with progressive somatic overgrowth. 3. Gigantism in children with accelerated linear growth. 4. Pituitary adenomas or tumors causing hypersecretion of growth hormone. 5. Hypopituitarism resulting from pituitary trauma, surgery, or radiation. 6. Laron syndrome, a rare genetic disorder characterized by growth hormone insensitivity. 7. Severe protein-calorie malnutrition in hospitalized or elderly patients. 8. Malabsorption syndromes affecting nutrient uptake in the gastrointestinal tract. 9. Hepatic insufficiency or liver cirrhosis, as the liver is the primary site of IGF-1 synthesis. 10. Chronic kidney disease, which can alter the clearance and binding proteins of IGF-1. 11. Uncontrolled diabetes mellitus, which can suppress hepatic IGF-1 production. 12. Hypothyroidism, which can lead to decreased growth hormone secretion and low IGF-1 levels. 13. Hyperthyroidism, which may occasionally cause elevated IGF-1 concentrations. 14. Efficacy of recombinant human growth hormone therapy. 15. Compliance with prescribed growth hormone treatment regimens. 16. Recurrence of growth hormone-secreting pituitary tumors post-resection. 17. Response to medical therapies for acromegaly, such as somatostatin analogs or receptor antagonists. 18. Normal physiological elevations during the pubertal growth spurt. 19. Age-related physiological decline in growth hormone axis activity. 20. Estrogen-induced suppression of hepatic IGF-1 synthesis in patients on oral estrogen therapy. 21. Elevated levels associated with pregnancy due to placental growth hormone production. 22. Decreased levels associated with chronic inflammatory states and high cytokine levels. 23. Nutritional recovery and positive nitrogen balance during dietary rehabilitation.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Lab is committed to providing rapid, accurate, and highly reliable diagnostic services to patients across Pakistan. The turnaround time for the Insulin Like Growth F-1 test is typically within 24 to 48 hours from the time of sample collection, depending on the specific laboratory branch and processing schedule. Because this is a specialized endocrine assay requiring precise automated immunoassay technology, the sample undergoes rigorous quality control checks before the final report is authorized by a consultant pathologist. Patients and their referring physicians can access test reports conveniently through multiple digital channels. Dr. Essa Lab offers an easy-to-use online report portal on their official website, where patients can view, download, and print their results using the unique lab ID and password provided on their receipt. Additionally, reports can be accessed via the Dr. Essa Lab mobile application or received directly through WhatsApp, ensuring that patients can share their results with their healthcare providers without delay, facilitating timely clinical decision-making.

Insulin Like Growth F-1 Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Serum IGF-1 Level (Children)	Concentrations within the established age- and sex-specific reference ranges, reflecting healthy skeletal and somatic development.	Decreased levels indicating growth hormone deficiency or malnutrition; elevated levels indicating pediatric gigantism.
Serum IGF-1 Level (Adults)	Stable concentrations aligned with adult reference intervals, indicating balanced metabolic and tissue maintenance.	Markedly elevated levels suggesting acromegaly or a pituitary tumor; decreased levels indicating adult growth hormone deficiency.
Growth Hormone (GH) Correlation	Normal physiological feedback loop with GH; IGF-1 levels remain stable throughout the day.	Disrupted feedback; persistently high IGF-1 despite fluctuating or suppressed GH, or low IGF-1 despite high GH (GH resistance).
Hepatic Synthesis Capacity	Normal liver function with adequate production of IGF-1 in response to circulating growth hormone.	Significantly reduced IGF-1 levels in patients with liver cirrhosis, hepatitis, or hepatic insufficiency.
Nutritional Status Marker	Adequate serum levels reflecting balanced dietary protein and caloric intake.	Suppressed IGF-1 levels indicating severe protein-energy malnutrition, anorexia, or active malabsorption.
Pituitary Gland Function	Intact pituitary secretion of growth hormone leading to normal downstream IGF-1 production.	Low IGF-1 due to hypopituitarism or pituitary macroadenoma compression; high IGF-1 due to a functioning somatotroph adenoma.
Therapeutic Response (rhGH)	IGF-1 levels maintained within the target therapeutic range for age and sex during growth hormone replacement.	Subtherapeutic levels indicating inadequate dosage; supratherapeutic levels indicating over-replacement and risk of side effects.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Insulin Like Growth F-1?

• Experienced healthcare professionals: Our team of highly qualified pathologists, clinical biochemists, and technologists ensures the highest standards of diagnostic accuracy.
• Patient-focused care: We prioritize patient comfort, safety, and convenience at every stage of the diagnostic process.
• Quality diagnostic services: Dr. Essa Lab utilizes state-of-the-art automated immunoassay platforms with rigorous internal and external quality control protocols.
• Professional reporting: All endocrine reports are thoroughly reviewed and signed by consultant pathologists to guarantee clinical reliability.
• Modern diagnostic approach: We integrate advanced laboratory technologies and international diagnostic standards to deliver precise results.
• Comfortable environment: Our diagnostic centers are designed to provide a clean, hygienic, and welcoming atmosphere for all patients.
• Convenient location: With an extensive network of branches across Karachi and other major cities, accessing our services is simple and convenient.
• Commitment to accurate diagnosis: Since 1987, Dr. Essa Lab has remained a trusted name in diagnostics, dedicated to supporting clinical decisions with integrity.

Frequently Asked Questions (FAQs)

What is the Insulin Like Growth F-1 test?

The Insulin Like Growth F-1 (IGF-1) test measures the amount of IGF-1 hormone in your blood. IGF-1 is a hormone produced mainly by the liver in response to growth hormone stimulation. It plays a vital role in childhood growth and adult metabolism. Because its levels remain stable in the blood throughout the day, it is a highly reliable marker for evaluating growth hormone production and diagnosing disorders like growth hormone deficiency, acromegaly, and gigantism.

Why has my doctor ordered an Insulin Like Growth F-1 test?

Your doctor may order this test if you or your child show symptoms of growth hormone disorders. In children, this includes slow growth, short stature, or delayed physical development. In adults, symptoms like abnormal enlargement of the hands, feet, or facial bones (acromegaly), chronic fatigue, or muscle weakness may prompt this test. It is also used to monitor the effectiveness of growth hormone replacement therapy or to evaluate pituitary gland function.

Is fasting required for the Insulin Like Growth F-1 test?

While fasting is not always strictly mandatory for a standalone IGF-1 test, it is highly recommended to fast for 8 to 12 hours before the blood draw. Fasting helps prevent dietary factors from interfering with the test results, especially if your doctor has ordered other concurrent tests like fasting growth hormone, glucose, or lipid levels. You should drink plenty of water to stay hydrated, which makes the blood draw easier.

How long does it take to get the Insulin Like Growth F-1 test results?

At Dr. Essa Lab, the turnaround time for the Insulin Like Growth F-1 test is typically between 24 to 48 hours. This specialized test requires precise automated analysis and is subject to strict quality control reviews by our consultant pathologists. Once the report is finalized, you will receive a notification, and you can easily download your report from our website, mobile app, or via WhatsApp.

Are there any risks or pain associated with this test?

The Insulin Like Growth F-1 test is a standard blood test involving a simple venipuncture, which carries minimal risks. You may feel a brief, mild pinch or stinging sensation when the needle is inserted into your vein. Some minor bruising, soreness, or lightheadedness may occur afterward, but these symptoms are temporary and resolve quickly. Our experienced phlebotomists use sterile, single-use equipment to ensure a safe and comfortable experience.